Company profile for NeuBase Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NeuBase Therapeutics, Inc., is accelerating the genetic revolution developing a new class of designer synthetic medicines.NeuBase's targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on ...
NeuBase Therapeutics, Inc., is accelerating the genetic revolution developing a new class of designer synthetic medicines.NeuBase's targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
700 Technology Drive Pittsburgh, PA 15219
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/04/05/2858735/0/en/NeuBase-Therapeutics-Announces-Receipt-of-Notice-from-Nasdaq.html

GLOBENEWSWIRE
05 Apr 2024

https://www.globenewswire.com//news-release/2023/09/08/2739989/0/en/NeuBase-Therapeutics-Issues-Statement-Regarding-Filing-By-Shareholder.html

GLOBENEWSWIRE
08 Sep 2023

https://www.globenewswire.com/news-release/2023/08/03/2717810/0/en/NeuBase-Therapeutics-to-Explore-Strategic-Alternatives.html

GLOBENEWSWIRE
03 Aug 2023

https://www.globenewswire.com/news-release/2023/06/30/2698075/0/en/NeuBase-Announces-Closing-of-5-Million-Concurrent-Registered-Direct-Offering-and-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
30 Jun 2023

https://www.globenewswire.com/news-release/2023/06/29/2696990/0/en/NeuBase-Presents-Non-Human-Primate-Data-Illustrating-Stealth-Editors-are-Non-Immunogenic-Opening-the-Door-to-Redosing.html

GLOBENEWSWIRE
29 Jun 2023

https://www.globenewswire.com/news-release/2023/06/28/2696563/0/en/NeuBase-Announces-5-Million-Concurrent-Registered-Direct-Offering-and-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
28 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty